Literature DB >> 1761551

Identification of a sequence of human activated protein C (residues 390-404) essential for its anticoagulant activity.

R M Mesters1, R A Houghten, J H Griffin.   

Abstract

Activated protein C (APC) exerts its physiologic anticoagulant role by proteolytic inactivation of the blood coagulation cofactors Va and VIIIa. To identify the regions on the surface that mediate anticoagulant activity, 26 synthetic peptides were prepared representing 90% of the human protein C heavy chain primary structure and tested for their ability to inhibit APC anticoagulant activity. Peptide-(390-404) specifically inhibited APC activity in activated partial thromboplastin time and Xa-1-stage coagulation assays in normal, in protein S-depleted and Factor VIII-deficient plasma with 50% inhibition at 5 microM peptide. Polyclonal antibodies raised against this peptide and immunoaffinity-purified on a protein C-Sepharose column inhibited APC anticoagulant activity in activated partial thromboplastin time and Xa-1-stage assays in normal, protein S-depleted, and Factor VIII-deficient plasma with half-maximal inhibition at 30 nM anti-(390-404) antibody. Neither the peptide-(390-404) nor the anti-(390-404) antibodies inhibited APC amidolytic activity or the reaction of APC with recombinant [Arg358] alpha 1-antitrypsin. Furthermore, in a purified system, peptide-(390-404) inhibited APC-catalyzed inactivation of Factor Va in the presence as well as in the absence of phospholipids with 50% inhibition at 4 microM peptide. These data suggest that the region containing residues 390-404 in APC is essential for anticoagulant activity and is available to interact with antibodies or with other proteins such as the macromolecular substrates Factors Va or VIIIa.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1761551

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va.

Authors:  Thomas J Cramer; John H Griffin; Andrew J Gale
Journal:  Pathophysiol Haemost Thromb       Date:  2010-05-22

2.  Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.

Authors:  Vikas Bhat; Annette von Drygalski; Andrew J Gale; John H Griffin; Laurent O Mosnier
Journal:  Thromb Haemost       Date:  2015-10-15       Impact factor: 5.249

3.  An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms.

Authors:  Annette von Drygalski; Vikas Bhat; Andrew J Gale; Patricia M Averell; Thomas J Cramer; Darlene J Elias; John H Griffin; Laurent O Mosnier
Journal:  Blood Adv       Date:  2020-08-11

4.  Binding sites for blood coagulation factor Xa and protein S involving residues 493-506 in factor Va.

Authors:  M J Heeb; Y Kojima; T M Hackeng; J H Griffin
Journal:  Protein Sci       Date:  1996-09       Impact factor: 6.725

5.  Interactions and inhibition of blood coagulation factor Va involving residues 311-325 of activated protein C.

Authors:  R M Mesters; M J Heeb; J H Griffin
Journal:  Protein Sci       Date:  1993-09       Impact factor: 6.725

6.  Models of the serine protease domain of the human antithrombotic plasma factor activated protein C and its zymogen.

Authors:  C L Fisher; J S Greengard; J H Griffin
Journal:  Protein Sci       Date:  1994-04       Impact factor: 6.725

7.  Function of the activated protein C (APC) autolysis loop in activated FVIII inactivation.

Authors:  Thomas J Cramer; Andrew J Gale
Journal:  Br J Haematol       Date:  2011-04-04       Impact factor: 6.998

8.  Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding.

Authors:  Andrew J Gale; Vikas Bhat; Jean-Luc Pellequer; John H Griffin; Laurent O Mosnier; Annette Von Drygalski
Journal:  Pharm Res       Date:  2016-03-09       Impact factor: 4.200

9.  Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant.

Authors:  A von Drygalski; T J Cramer; V Bhat; J H Griffin; A J Gale; L O Mosnier
Journal:  J Thromb Haemost       Date:  2014       Impact factor: 5.824

10.  Detailed mechanisms of the inactivation of factor VIIIa by activated protein C in the presence of its cofactors, protein S and factor V.

Authors:  Andrew J Gale; Thomas J Cramer; Diana Rozenshteyn; Jason R Cruz
Journal:  J Biol Chem       Date:  2008-04-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.